SCHEMBL2969626

SCHEMBL2969626

Cc1ccc(C(=O)Nc2nccs2)cc1NC(=O)c1ccc(N)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.74
NPC1 O15118 8/20 0.74
SMN1; SMN2 Q16637 4/20 0.74
LMNA P02545 2/20 0.74
RECQL P46063 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
ADORA2A P29274 4/20 0.55
ADORA1 P30542 1/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
HSD17B10 Q99714 2/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
ESR2 Q92731 1/20 0.55
AGER Q15109 1/20 0.55
MAPK1 P28482 2/20 0.55
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
SCD O00767 1/20 0.53
USP2 O75604 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3200814 0.86 NPC1 (1.00) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL2977438 0.84 NPC1 (0.76) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL1119373 0.82 RAB9A (0.71) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3190864 0.81 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4295738 0.79 NPC1 (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3223685 0.78 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4292558 0.78 RAB9A (0.64) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3892750 0.77 RAB9A (0.68) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL2980539 0.77 NPC1 (0.61) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL4290911 0.77 RAB9A (0.77) RAB9ANPC1SMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US claimed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP claimed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO claimed
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 RAB9A 1437/4885NPC1 2786/4885SMN1; SMN2 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.